What:Relypsa (NASDAQ: RLYP) , a biopharmaceutical company developing gastrointestinal medicines, saw its shares surge 58% higher at the opening bell today on the news that the Swiss-based Galenica ...

As hype around new treatments for the blood disorder hyperkalemia continues unabated after AstraZeneca's $2.7 billion buyout of ZS Pharma last year, Relypsa ($RLYP ...

It's not every day you see an FDA approval send shares lower. So what: The company has announced that its first drug, named Veltassa, has been approved for sale in the U.S. to treat hyperkalemia, or ...

Shares jump in response to an analyst upgrade and positive clinical data, but investors have more pressing concerns ahead. So what: Relypsa presented data from two studies at the 53rd European Renal ...

Approximately 3 million people with chronic kidney disease (CKD) and/or heart failure in the United States have hyperkalemia In clinical trials, Veltassa significantly reduced blood potassium and kept ...

SOURCE: FLICKR USER STEVE JURVETSON. What:Swirling rumors that an acquirer might step up to buy the company caused shares inRelypsa, to soar 67.6% higher today. So what: The company has been the ...

· Veltassa will be distributed to patients via two nationally-recognized specialty pharmacies · Hospitals will receive Veltassa through a network of authorized specialty distributors · Relypsa's ...

So what: The terms of this deal received a mixed reception among Relypsa's shareholder base. The apparent reason for the discontent is that the Street's high-end price target (before this deal was ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced the completion of a Series B financing totaling $70 million.

The U.S. Food and Drug Administration approved Relypsa Inc's drug to treat potentially fatal levels of potassium in patients with chronic kidney disease or heart problems. The drug, Veltassa, is ...

What:Shares of U.S.-basedRelypsa(NASDAQ: RLYP), a biopharma developing polymeric medicines for disorders of the gastrointestinal tract, gained more than 72% last month,according to data fromS&P Global ...